GlassScriptPhysician profile
Morgan W Hubeli
NPI 1043885692
$15,400.28
in general payments reported to CMS, 2019-2025
33 companies · $8,300 in 2025
The $8,300 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $2,127 · 2023: $1,364 · 2024: $3,219 · 2025: $8,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,073 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,450 · Education: $214 · Consulting Fee: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,073.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,450.00 |
| Education | $213.54 |
| Consulting Fee | $146.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $4,960.69 | 2021-2025 | Karbinal |
| Astrazeneca Pharmaceuticals LP | $2,006.60 | 2022-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,368.18 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,300.01 | 2022-2025 | Dupixent |
| Csl Behring | $713.99 | 2021-2025 | Hizentra, Hemgenix, Haegarda |
| Genzyme Corporation | $553.29 | 2021-2025 | |
| Ars Pharmaceuticals Operations, INC. | $538.47 | 2025 | Neffy |
| Grifols USA, LLC | $470.92 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Amgen INC. | $429.55 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $379.78 | 2021-2025 | Takhzyro, Eohilia, Cuvitru |
| Novartis Pharmaceuticals Corporation | $349.42 | 2024-2025 | |
| Kaleo, INC. | $250.64 | 2022-2024 | Auvi-Q |
| Octapharma USA, INC. | $247.80 | 2023-2025 | Panzyga, Cutaquig |
| Abbvie INC. | $230.36 | 2022-2025 | |
| Incyte Corporation | $217.34 | 2022-2025 | Opzelura |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $189.29 | 2025 | Vtama, Nexplanon |
| Optinose US, INC. | $182.71 | 2021-2025 | |
| Pharming Healthcare, INC. | $172.50 | 2024-2025 | Ruconest |
| Pfizer INC. | $162.78 | 2024-2025 | |
| Adma Biomanufacturing LLC | $146.60 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $89.36 | 2023-2024 | Ryaltris |
| Ionis Pharmaceuticals, INC. | $74.66 | 2025 | Dawnzera |
| Genentech USA, INC. | $69.88 | 2022-2024 | Xolair |
| Biocryst US Sales Co., LLC | $63.31 | 2024 | Orladeyo |
| Azurity Pharmaceuticals, INC. | $40.61 | 2025 | Alvesco |
| Galderma Laboratories, L.P. | $34.61 | 2025 | Nemluvio |
| Siemens Medical Solutions USA, INC. | $29.68 | 2025 | Immulite 1000 Immunoassay System |
| Greer Laboratories, INC. | $28.24 | 2025 | Oralair |
| Phadia US INC. | $25.88 | 2022 | |
| Tersera Therapeutics LLC | $22.27 | 2022 | |
| Invivyd INC | $21.45 | 2024 | Pemgarda |
| Gc Biopharma USA, INC. | $17.13 | 2025 | Alyglo |
| Novo Nordisk INC | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Hubeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.